[1]
Zhou, P.; Yang, X-L.; Wang, X-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H-R.; Zhu, Y.; Li, B.; Huang, C-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579, 270-273.
[2]
Lam, T.T-Y.; Shum, M.H-H.; Zhu, H-C.; Tong, Y-G.; Ni, X-B.; Liao, Y-S.; Wei, W.; Cheung, W.Y-M.; Li, W-J.; Li, L-F. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. Nature, 2020.
[3]
Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K.S.; Lau, E.H.; Wong, J.Y. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England. J. Med., 2020, 383(13), 1199-1207.
[4]
Guan, W.-J.; Ni, Z.-Y.; Hu, Y.; Liang, W.-H.; Ou, C.-Q.; He, J.-X.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D.S. linical characteristics of 2019 novel coronavirus infection in China. Eng. J. Med., 2020.
[5]
Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov., 2020, 19(3), 149-150.
[6]
Chu, C.; Cheng, V.; Hung, I.; Wong, M.; Chan, K.; Chan, K.; Kao, R.; Poon, L.; Wong, C.; Guan, Y. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 2004, 59(3), 252-256.
[7]
de Wilde, A.H.; Jochmans, D.; Posthuma, C.C.; Zevenhoven-Dobbe, J.C.; van Nieuwkoop, S.; Bestebroer, T.M.; van den Hoogen, B.G.; Neyts, J.; Snijder, E.J. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother., 2014, 58(8), 4875-4884.
[8]
Laguno, M.; Murillas, J.; Blanco, J.L.; Martínez, E.; Miquel, R.; Sánchez-Tapias, J.M.; Bargallo, X.; García-Criado, A.; de Lazzari, E.; Larrousse, M. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids, 2004, 18(13), 27-36.
[9]
Goswami, B.B.; Borek, E.; Sharma, O.K.; Fujitaki, J.; Smith, R.A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Bioph. Res. Com., 1979, 89(3), 830-836.
[10]
Barnard, D.L.; Day, C.W.; Bailey, K.; Heiner, M.; Montgomery, R.; Lauridsen, L.; Winslow, S.; Hoopes, J.; Li, J.K-K.; Lee, J. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res., 2006, 71(1), 53-63.
[11]
Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, 2(1), 69.
[12]
Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271.
[13]
Boriskin, Y.; Leneva, I.; Pecheur, E-I.; Polyak, S. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr. Med. Chem., 2008, 15(10), 997-1005.
[14]
Blaising, J.; Polyak, S.J.; Pécheur, E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res., 2014, 107, 84-94.
[15]
Holshue, M.L.; DeBolt, C.; Lindquist, S.; Lofy, K.H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A. First case of 2019 novel coronavirus in the United States. New England. J. Med., 2020, 382(10), 929-936.
